OMNIlife plans to use the proceeds of the financing to continue expansion of its hip and knee replacement implant product lines as well as to complete commercial development of its U.S. Food and Drug Administration-cleared OMNInav hip replacement solution
More Articles on Devices:
Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws
